Context Therapeutics Inc. (CNTX)
- Previous Close
1.7500 - Open
1.7079 - Bid 1.7000 x 200
- Ask 1.7300 x 400
- Day's Range
1.7029 - 1.7600 - 52 Week Range
0.7700 - 2.1200 - Volume
66,424 - Avg. Volume
575,676 - Market Cap (intraday)
128.247M - Beta (5Y Monthly) 2.32
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.40
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
www.contexttherapeutics.comRecent News: CNTX
Performance Overview: CNTX
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CNTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CNTX
Valuation Measures
Market Cap
128.25M
Enterprise Value
103.12M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
15.19
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-64.59%
Return on Equity (ttm)
-114.72%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.32M
Diluted EPS (ttm)
-1.3300
Balance Sheet and Cash Flow
Total Cash (mrq)
10.09M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-12.27M